BLTE - Rasio utang marang kapitalisasi buku Belite Bio, Inc

Belite Bio, Inc (BLTE) develops ophthalmological drugs, leveraging partnerships with leading scientific centers to accelerate drug commercialization. The company's growth is based on Tinlarebant trials and the prospects of combating macular degeneration, with the metric standing at 0.00. This chart of the market price visualizes the asset's price action. Business stability is ensured by patent protection and minimal impact from global political conflicts.

BLTE (Belite Bio, Inc.) riwayat Utang marang nilai buku saka 28.04.2023 nganti 28.10.2026

Rincian metrik lan analitis perusahaan Belite Bio, Inc (BLTE)

- rega lan prakiraan konsensus rega:

Rega saham Belite Bio Corp|BLTE - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar Belite Bio Pharma|BLTE - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Belite Bio|BLTE - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku belitebio.com|BLTE - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas Belite Bio, Inc|BLTE - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal belitebio.com|BLTE - Utang kumulatif perusahaan|Utang marang nilai buku Belite Bio Pharma

Analisis kabeh metrik perusahaan:Belite Bio, Inc. - BLTE

This ratio measures the degree of financial autonomy by comparing total liabilities to equity to assess the debt load. By analyzing the debt-to-book capitalization ratio of Belite Bio, Inc (BLTE) on GURU.Markets, an investor can track the solvency dynamics of Belite Bio, Inc (BLTE), which is critical when outsourcing production to third-party contractors (CRO/CMO) to minimize capital expenditures for drug development.

Pesaing Belite Bio, Inc

Utang-utang marang kapitalisasi buku ALC (Alcon Inc.)|bausch.com - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Glaukos (GKOS)|APLS: Rasio utang marang aset resik|OCUL (Ocular Therapeutix Corp) - Rasio utang marang kapitalisasi buku|Harrow Corp (HROW) - Utang marang nilai buku|VRDN (Viridian Therapeutics) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku lenz-tx.com (LENZ)|Oculis Pharma (OCS) - Utang marang nilai buku|Rasio utang marang aset resik EyePoint Pharmaceuticals Inc (EYPT)|KOD: Utang-utang marang kapitalisasi buku|ALDX - Utang-utang marang nilai buku|KALA (Kala Pharmaceuticals) - Utang marang nilai buku|IRD - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku OKYO|ADVM (Adverum Biotechnologies, Inc.) - Utang-utang marang nilai buku|OTLK: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Clearside Corp|Utang-utang marang kapitalisasi buku NovaBay Pharmaceuticals (NBY)|Rasio utang marang kapitalisasi buku kiorapharma.com (KPRX)|ALIM: Utang-utang marang kapitalisasi buku|Eyenovia Inc. - Utang-utang marang nilai buku|GHSI - Rasio utang marang kapitalisasi buku|OCUP - Rasio utang marang kapitalisasi buku|Opthea Limited - Utang-utang marang kapitalisasi buku